Apheresis days required for harvesting CD34 cells predicts hematopoietic recovery and survival following autologous transplantation

Bone Marrow Transplantation

Volumn 46, Issue 12, 2011, Pages 1519-1525

  Malik, S ^a   Bolwell, B ^b   Rybicki, L ^a   Copelan, O ^b   Duong, H ^b   Dean, R ^b   Sobecks, R ^b   Kalaycio, M ^b   Sweetenham, J ^b   Pohlman, B ^b   Andresen, S ^b   Tench, S ^b   Koo, A ^b   Figueroa, P ^a   Copelan, E ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

apheresis days; autologous transplantation; CD34+ cells; hematopoietic recovery

Indexed keywords

ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; AUTOTRANSPLANTATION; CANCER MORTALITY; CANCER RELAPSE; CANCER THERAPY; CD34 SELECTION; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; HUMAN; LEUKOCYTE ACTIVATION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; PRIORITY JOURNAL; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD COMPONENT REMOVAL; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLATELET COUNT; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84856081367     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.336     Document Type: Article

References (19)

1. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
2. Copelan EA, Ceselski SK, Ezzone S, Lasky LC, Penza SK, Bechtel TP et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol 1997; 15: 759-765. (Pubitemid 27074246)
3. + cell dose. Bone Marrow Transplant 1999; 23: 1237-1243. (Pubitemid 29312929)
4. Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D et al. Stem cell mobilization. Hematology 2003, 419-437.
5. - cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients. J Clin Oncol 1998; 16: 2093-2104. (Pubitemid 28265046)
6. + hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation. Haematologica 1999; 84: 517-524. (Pubitemid 29323260)
7. Specchia G, Pastore D, Mestice A, Liso A, Carluccio P, LeoM et al. Early and long-term engraftment after autologous peripheral stem cell transplantation in acute myeloid leukemia patients. Acta Haematol 2006; 116: 229-237. (Pubitemid 44795901)
8. - cells in posttransplant hematopoietic recovery. Stem Cells 1998; 16 (Suppl 1): 113-122.
9. Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelopdysplasia and acute myelogenous leukemia. J Clin Oncol 2006; 24: 3604-3610. (Pubitemid 46630533)
10. + cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148-3155. (Pubitemid 28193863)
11. Hass R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje Met al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794. (Pubitemid 24175570)
12. Dreger P, Kloss M, Petersen B, Haferlach T, Loffler H, Loeffler M et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970-3978.
13. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-1056.
14. Zijlmans MJ, Visser JW, Laterveer L, Kleiverda K, Heemskerk DP, Kluin PM et al. The early phase of engraftment after murine blood cell transplantation is mediated by hematopoietic stem cells. Proc Natl Acad Sci 1998; 95: 725-729. (Pubitemid 28083811)
15. D'Hondt L, Lambert JF, Damon J, Benoit BO, Cerny J, Carlson JE et al. Engraftment of post 5-fluorouracil murine marrow into minimally myeloablated (100 cGy) murine hosts. J Hematotherapy Stem Cell Res 2002; 11: 483-490. (Pubitemid 34615033)
16. Specchia G, Pastore D, Mestice A, Liso A, Carluccio P, LeoM et al. Early and long-term engraftment after autologous peripheral stem cell transplantation in acute myeloid leukemia patients. Acta Haematol 2006; 116: 229-237. (Pubitemid 44795901)
17. Bonsignore MR, Morici G, Santoro A, Pagano M, Cascio L, Bonanno A et al. Circulating hematopoietic progenitor cells in runners. J Appl Physiol 2002; 93: 1691-1697. (Pubitemid 36082981)
18. + cell populations based on global gene and microRNA expression signatures. Blood 2009; 114: 2530-2541.
19. Kang Y, Chen B, Deoliveira D, Mito J, Chao NJ. Plerixafor (Mozobils) selectively enhances donor hematopoietic cell engraftment. Blood (ASH Annual Meeting Abstracts) 2009; 114; abstract 368.